The recent emergence of a novel coronavirus associated with an ongoing outbreak of pneumonia (Covid-2019) resulted in infections of more than 72,000 people and claimed over 1,800 lives. Coronavirus spike (S) glycoprotein trimers promote entry into cells and are the main target of the humoral immune response. We show here that SARS-CoV-2 S mediates entry in VeroE6 cells and in BHK cells transiently transfected with human ACE2, establishing ACE2 as a functional receptor for this novel coronavirus. We further demonstrate that the receptor-binding domains of SARS-CoV-2 S and SARS-CoV S bind with similar affinities to human ACE2, which correlates with the efficient spread of SARS-CoV-2 among humans. We found that the SARS-CoV-2 S glycoprotein harbors a furin cleavage site at the boundary between the S 1 /S 2 subunits, which is processed during biogenesis and sets this virus apart from SARS-CoV and other SARS-related CoVs. We determined a cryo-electron microscopy structure of the SARS-CoV-2 S ectodomain trimer, demonstrating spontaneous opening of the receptor-binding domain, and providing a blueprint for the design of vaccines and inhibitors of viral entry. Finally, we demonstrate that SARS-CoV S murine polyclonal sera potently inhibited SARS-CoV-2 S-mediated entry into target cells, thereby indicating that cross-neutralizing antibodies targeting conserved S epitopes can be elicited upon vaccination.
INTRODUCTION
Three coronaviruses have crossed the species barrier to cause deadly pneumonia in humans since the beginning of the 21 st century: severe acute respiratory syndrome coronavirus (SARS-CoV) (Drosten et al., 2003; Ksiazek et al., 2003) , Middle-East respiratory syndrome coronavirus (Zaki et al., 2012 ) (MERS-CoV) and SARS-CoV-2 (Huang et al., 2020; Zhu et al., 2020) . SARS-CoV emerged in the Guangdong province of China in 2002 and spread to five continents through air travel routes, infecting 8,098 people and causing 774 deaths. In 2012, MERS-CoV emerged in the Arabian Peninsula, where it remains a major public health concern, and was exported to 27 countries, infecting a total of ~2,494 individuals and claiming 858 lives. A previously unknown coronavirus, named SARS-CoV-2, was discovered in December 2019 in Wuhan, Hubei Province of China and was sequenced and isolated by January 2020 (Zhou et al., 2020; Zhu et al., 2020) . SARS-CoV-2 is associated with an ongoing outbreak of atypical pneumonia (Covid-2019) that has affected over 72,436 people and killed more than 1,868 of them in 29 countries as of February 15 th 2020. On January 30 th 2020, the World Health Organization declared the SARS-CoV-2 epidemic as a public health emergency of international concern.
MERS-CoV was suggested to originate from bats but the reservoir host fueling spillover to humans is unequivocally dromedary camels (Haagmans et al., 2014; Memish et al., 2013) . Both SARS-CoV and SARS-CoV-2 are closely related to each other and originated in bats which most likely serve as reservoir host for these two viruses (Ge et al., 2013; Hu et al., 2017; Li et al., 2005b; Yang et al., 2015a; Zhou et al., 2020) . Whereas palm civets and racoon dogs have been recognized as an intermediate host for zoonotic transmission of SARS-CoV between bats and humans (Guan et al., 2003; Kan et al., 2005; Wang et al., 2005) , the intermediate host of SARS-CoV-2 remains unknown. The recurrent spillovers of coronaviruses in humans along with detection of numerous coronaviruses in bats, including many SARS-related coronaviruses (SARSr-CoVs), suggest that future zoonotic transmission events may continue to occur (Anthony et al., 2017; Ge et al., 2013; Hu et al., 2017; Li et al., 2005b; Menachery et al., 2015; Menachery et al., 2016; Yang et al., 2015a; Zhou et al., 2020) .
In addition to the highly pathogenic zoonotic pathogens SARS-CoV, MERS-CoV and SARS-CoV-2, all belonging to the β-coronavirus genus, four low pathogenicity coronaviruses are endemic in humans: HCoV-OC43, HCoV-HKU1, HCoV-NL63 and HCoV-229E.To date, no therapeutics or vaccines are approved against any humaninfecting coronaviruses.
Coronavirus entry into host cells is mediated by the transmembrane spike (S) glycoprotein that forms homotrimers protruding from the viral surface (Tortorici and Veesler, 2019) . S comprises two functional subunits responsible for binding to the host cell receptor (S 1 subunit) and fusion of the viral and cellular membranes (S 2 subunit).
For many CoVs, S is cleaved at the boundary between the S 1 and S 2 subunits which remain non-covalently bound in the prefusion conformation (Belouzard et al., 2009; Bosch et al., 2003; Burkard et al., 2014; Kirchdoerfer et al., 2016; Millet and Whittaker, 2014, 2015; Park et al., 2016; Walls et al., 2016a) . The distal S 1 subunit comprises the receptor-binding domain(s), and contributes to stabilization of the prefusion state of the Western blot analysis of SARS-CoV-2 S-MLV, SARS-CoV-2 S fur/mut -MLV and SARS-CoV S-MLV pseudovirions using an anti-SARS-CoV S 2 antibody.
SARS-CoV-2 recognizes human ACE2 with comparable affinity than SARS-CoV
The binding affinity of SARS-CoV for hACE2 correlate with the overall rate of viral replication in distinct species, transmissibility and disease severity (Guan et al., 2003; Li et al., 2004; Li et al., 2005c; Wan et al., 2020) . Indeed, specific S B mutations enabled efficient binding to hACE2 of SARS-CoV isolates from the three phases of the 2002-2003 epidemic, which were associated with marked disease severity (Consortium, 2004; Kan et al., 2005; Li et al., 2005c; Sui et al., 2004) . In contrast, SARS-CoV isolates detected during the brief 2003-2004 re-emergence interacted more weakly with hACE2, but tightly with civet ACE2, and had low pathogenicity and transmissibility (Consortium, 2004; Kan et al., 2005; Li et al., 2005c) .
To understand the contribution of receptor interaction to the infectivity of SARS-CoV-2, we characterized engagement of hACE2 by SARS-CoV-2 S B and SARS-CoV S B side-by-side. We used biolayer interferometry to study binding kinetics and affinity of the purified hACE2 ectodomain to SARS-CoV-2 S B and SARS-CoV S B immobilized at the surface of biosensors. We found that hACE2 bound to SARS-CoV-2 S B and SARS-CoV S B with respective equilibrium dissociation constants of 2.9 nM (Fig. 2 A) and 7.7 nM (Fig. 2 B) , and comparable kinetic rate constants although the off-rate was slightly higher for SARS-CoV S B (Table 1) . Previous structural work identified 14 positions that are key for binding of SARS-CoV S B to hACE2: T402, R426, Y436, Y440, Y442, L472, N473, Y475, N479, Y484, T486, T487, G488 and Y491 (Li et al., 2005a) . Analysis of the 104 SARS-CoV-2 genome sequences available from GISAID (Elbe and Buckland-Merrett, 2017) shows that 8 out of these 14 positions are strictly conserved in SARS-CoV-2 S B whereas the other 6 positions are (semi)-conservatively substituted: R426 SARS-CoV N448 SARS-CoV-2 , Y442 SARS-CoV L464 SARS-CoV-2 , L472 SARS-CoV F495 SARS-CoV-2 , N479 SARS-CoV Q502 SARS-CoV-2 , Y484 SARS-CoV Q507 SARS-CoV-2 , T487 SARS-CoV N510 SARS-CoV-2 ( Fig. 2 C) . The conservation of many key contact residues could explain the similar binding affinities of SARS-CoV-2 S B and SARS-CoV S B for hACE2. No mutations of residues predicted to contact hACE2 have been observed among SARS-CoV-2 S sequences available to date. However, we note that SARSr-CoV ZXC21 and ZC45, which harbor the most closely related S sequences after SARSr-CoV RaTG13, comprise two deletions in the RBD that could affect binding to hACE2 (between SARS-CoV-2 S residues 482-489 and 494-499) (Fig. S 1) . Collectively, these results suggest that SARS-CoV-2 is at least as well adapted to the hACE2 orthologue as the [2002] [2003] epidemic strains of SARS-CoV, which could explain the efficient transduction efficiency mediated by their respective S glycoproteins ( Fig. 1 A-B ) and the current rapid SARS-CoV-2 transmission in humans. 
Architecture of the SARS-CoV-2 spike glycoprotein trimer
To enable single-particle cryoEM study of the SARS-CoV-2 S glycoprotein, we designed a prefusion stabilized ectodomain trimer construct with an abrogated furin S 1 /S 2 cleavage site (Tortorici et al., 2019; Walls et al., 2017a; Walls et al., 2016a; Walls et al., 2019) , two consecutive proline stabilizing mutations (Kirchdoerfer et al., 2018; Pallesen et al., 2017 ) and a C-terminal foldon trimerization domain (Miroshnikov et al., 1998) . 3D classification of the cryoEM data revealed the presence of multiple conformational states of SARS-CoV-2 S corresponding to distinct organization of the S B domains within the S 1 apex. Approximately half of the particle images selected correspond to trimers harboring a single S B domain opened whereas the remaining half was accounted for by closed trimers with the 3 S B domains closed. The observed conformational variability of S B domains is reminiscent of observations made with SARS-CoV S and MERS-CoV S trimers although we did not detect trimers with two S B domains open and the distribution of particles across the S conformational landscape varies among studies (Gui et al., 2017; Kirchdoerfer et al., 2018; Pallesen et al., 2017;  Overall, the SARS-CoV-2 S ectodomain is a 160Å-long trimer with a triangular crosssection, resembling the closely related SARS-CoV S structure (Fig S3 A-F) (Gui et al., 2017; Kirchdoerfer et al., 2018; Song et al., 2018; Walls et al., 2019; Yuan et al., 2017) .
As is the case for other β-coronavirus S glycoproteins, including SARS-CoV S (Gui et al., 2017; Kirchdoerfer et al., 2018; Pallesen et al., 2017; Park et al., 2019; Song et al., 2018; Tortorici et al., 2019; Walls et al., 2016a; Walls et al., 2016b; Walls et al., 2019; Yuan et al., 2017) , the S 1 subunit has a V-shaped architecture (Fig S3 B-E) . In the closed S trimer, the three hACE2-recognition motifs, whose location was inferred based on the crystal structure of SARS-CoV S B in complex with hACE2 (Li et al., 2005a) , are buried at the interface between protomers. As a result, SARS-CoV-2 S B opening is expected to be necessary for interacting with ACE2 at the host cell surface and initiating the conformational changes leading to cleavage of the S 2 ' site, membrane fusion and viral entry (Gui et al., 2017; Kirchdoerfer et al., 2018; Millet and Whittaker, 2014; Pallesen et al., 2017; Park et al., 2016; Song et al., 2018; Walls et al., 2019; Yuan et al., 2017) .
As the SARS-CoV-2 and SARS-CoV S 2 subunits share 88% sequence identity, they are structurally conserved and can be superimposed with 1.2 Å rmsd over 417 aligned Cα positions ( Fig S3 E-F ). Only the most N-terminal part of the fusion peptide is resolved in the map, as was the case for previously determined SARS-CoV S structures. The sequence and conformational conservation of the fusion peptide region observed across SARS-CoV-2 S and SARS-CoV S suggests that antibodies targeting this functionally important motif might cross-react and neutralize the two viruses as well as related coronaviruses (Fig S3 G-H) We previously showed that coronavirus S glycoproteins are densely decorated by heterogeneous N-linked glycans protruding from the trimer surface (Walls et al., 2016b; Walls et al., 2019; Xiong et al., 2017) . These oligosaccharides participate in S folding (Rossen et al., 1998) , they affect priming by host proteases (Yang et al., 2015b) and modulate antibody recognition (Pallesen et al., 2017; Walls et al., 2019) . SARS-CoV-2 S comprise 22 N-linked glycosylation sequons per protomer and 16 of them are resolved in the cryoEM map ( Fig. 4) . By comparison, SARS-CoV S possesses 23 Nlinked glycosylation sequons per protomer and we previously confirmed experimentally that at least 19 of them are glycosylated (Walls et al., 2019) . 20 out of 22 SARS-CoV-2 S N-linked glycosylation sequons are conserved in SARS-CoV S (Table 3) . Specifically, 9 out of 13 glycans in the S 1 subunit and all 9 glycans in the S 2 subunit are conserved among SARS-CoV-2 S and SARS-CoV S. Furthermore, S 2 oligosaccharides are mostly conserved across SARSr-CoV S glycoproteins, suggesting that accessibility of the fusion machinery to antibodies will be comparable among these viruses. 
SARS-CoV S elicits neutralizing antibodies against SARS-CoV-2 S
Mapping of the sequence conservation across multiple sarbecovirus S sequences underscores that the S 2 fusion machinery is more conserved than the S 1 subunit with the highest divergence found within S A and S B (Fig. 5A-B ). These observations are in line with (i) the fact that some, but not all of these viruses use ACE2 as entry receptor (Ge et al., 2013; Ren et al., 2008; Yang et al., 2015a) ; and (ii) that the S 1 subunit is more exposed at the viral surface than the fusion machinery, and is likely to be subject to a more stringent selection pressure from the immune system.
Based on these observations, we hypothesized that exposure to one of the two viruses could elicit cross-reactive and potentially neutralizing antibodies against the other virus. We therefore investigated the ability of plasma from four mice immunized with a stabilized SARS-CoV S to inhibit SARS-CoV-2 S-and SARS-CoV S-mediated entry into target cells. All sera tested completely inhibited transduction of SARS-CoV S-MLV and reduced SARS-CoV-2 S-MLV transduction to ~10% of control in VeroE6 cells 
DISCUSSION
Receptor recognition is the first step of viral infection and is a key determinant of host cell and tissue tropism. Enhanced binding affinity between SARS-CoV S and hACE2 was proposed to correlate with increased virus transmissibility and disease severity in humans (Li et al., 2005c) . Indeed, SARS-CoV isolates from the three phases of the 2002-2003 epidemic were more efficiently transmitted among humans and more pathogenic than the isolates associated with the 2003-2004 re-emergence that caused only a few cases, in line with their binding affinities for hACE2 (Consortium, 2004; Kan et al., 2005; Li et al., 2005c) . Moreover, the ability to engage ACE2 from different animal species appears to reflect host susceptibility to SARS-CoV infection and facilitated the jump of the virus from animals to humans (Li, 2008; Li et al., 2004) . We report here that SARS-CoV-2 uses hACE2 as entry receptor to which it binds with similar affinity than the 2002-2003 SARS-CoV isolates which suggests it can spread efficiently in humans, in agreement with the numerous SARS-CoV-2 human-to-human transmission events reported to date.
Besides binding to host cell receptors, priming of the S glycoprotein by host proteases through cleavage at the S 1 /S 2 and the S 2 ' sites is another crucial factor modulating tropism and pathogenicity (Millet and Whittaker, 2015) . For instance, entry of the MERS-CoV-related bat coronavirus HKU4 into human cells required addition of exogenous trypsin, indicating that S proteolytic activation of this bat virus did not occur in human cells (despite its ability to recognize human DPP4) (Wang et al., 2014; Yang et al., 2014) . Subsequent work suggested that a glycan present near the S 1 /S 2 boundary accounted for the lack of proteolytic priming of HKU4 S and that its removal enhanced pseudovirus entry in human cells (Yang et al., 2015b) . The presence of a polybasic cleavage site, that can be processed by furin-like proteases, is a signature of several highly pathogenic avian influenza viruses and pathogenic Newcastle disease virus (Klenk and Garten, 1994; Steinhauer, 1999) . Strikingly, SARS-CoV-2 S harbors a furin cleavage site at the S 1 /S 2 boundary, which is processed during biosynthesis. The presence of a furin cleavage site sets SARS-CoV-2 S apart from SARS-CoV S (and SARSr-CoV S) that possesses a monobasic S 1 /S 2 cleavage site processed upon entry of target cells (Belouzard et al., 2009; Bosch et al., 2008; Glowacka et al., 2011; Matsuyama et al., 2010; Millet and Whittaker, 2015; Shulla et al., 2011) . We speculate that the almost ubiquitous expression of furin-like proteases could participate in expanding SARS-CoV-2 cell and tissue tropism, relative to SARS-CoV, as well as increase its transmissibility and/or alter its pathogenicity.
We previously suggested coronaviruses use conformational masking and glycan shielding to limit recognition by the immune response of infected hosts (Walls et al., 2016b; Walls et al., 2019; Xiong et al., 2017) . Similarly to SARS-CoV S and MERS-CoV S (Gui et al., 2017; Kirchdoerfer et al., 2018; Pallesen et al., 2017; Song et al., 2018; Walls et al., 2019; Yuan et al., 2017) , we found that the SARS-CoV-2 S trimer exist in multiple, distinct conformational states resulting from S B opening at the trimer apex.
These structural changes are necessary for receptor engagement of these three viruses and lead to initiation of fusogenic conformational changes (Song et al., 2018; Walls et al., 2017b; Walls et al., 2019) . In contrast, only closed S trimers have been detected for ). Collectively, these data underscores that S glycoprotein trimers found in highly pathogenic human coronaviruses appear to exist in partially opened states whereas they remain largely closed in human coronaviruses associated with common colds.
Based on the aforementioned data correlating the binding affinity of SARS-CoV for hACE2 with the rate of transmissibility, viral replication in distinct species and disease severity (Guan et al., 2003; Li et al., 2004; Li et al., 2005c; Wan et al., 2020) , we hypothesize that the most pathogenic coronaviruses will exhibit S glycoprotein trimers spontaneously sampling closed and open conformations, as is the case for SARS-CoV-2, SARS-CoV and MERS-CoV.
The striking structural similarity and sequence conservation among the SARS-CoV-2 S and SARS-CoV S glycoproteins emphasize the close relationship between these two viruses that recognize hACE2 to enter target cells. This resemblance is further strengthened by our finding that SARS-CoV S elicited polyclonal Ab responses potently neutralizing SARS-CoV-2 S-mediated entry into cells. We surmise most of these Abs target the highly conserved S 2 subunit (including the fusion peptide region) based on its structural similarity across SARS-CoV-2 and SARS-CoV and previous reports showing that sera from SARS-CoV-infected individuals target this region (Zhang et al., 2004) . We note that most SARS-CoV neutralizing Abs isolated to date target the S B domain and several of them recognize the RBM and prevent receptor engagement (Hwang et al., 2006; Rockx et al., 2008; Rockx et al., 2010; Traggiai et al., 2004; Walls et al., 2019) . As the SARS-CoV-2 and SARS-CoV S B domains share 75% amino acid sequence identity, future work will be necessary to evaluate how many of these antibodies neutralize the newly emerged coronavirus. These findings also indicate that it might be difficult to distinguish exposure to SARS-CoV-2 from other SARSr-CoVs in serological studies using S ectodomain trimers and that specific assays will need to be designed. Our results provide a structural framework to identify conserved and accessible epitopes across S glycoproteins that will support ongoing vaccine design efforts. Finally, elicitation of diverse, polyclonal Ab responses might prove key in light of the diversity of viruses circulating in animal reservoirs and to prevent the possible emergence of viral neutralization escape mutants.
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MATERIALS AND METHODS
Transient expression of SARS-CoV-2 and SARS-CoV S B
The 
Transient expression of hACE2
Expression and purification of human angiotensin-converting enzyme ectodomain (ACE2, residues 1-614) fused to the Fc region of human IgG (hFc) was performed as 
Pseudovirus production
MLV-based SARS-CoV S, SARS-CoV-2 S, and SARS-CoV-2 S fur/mut pseudotypes were prepared as previously described (Millet and Whittaker, 2016 added to the cells in equivalent culturing volume and incubated in the dark for 10 minutes prior to reading on a Varioskan LUX plate reader (ThermoFisher).
Measurements were done in triplicate and relative luciferase units (RLU) were plotted.
Biolayer interferometry
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